

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on:

Date:

April 18, 2003

By:

Jennifer Mahan

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Zalipsky and Gabizon

APPLICATION No.: 10/714,085

FILED: November 14, 2003

FOR: METHOD FOR TREATING MULTI-DRUG  
RESISTANT TUMORS

EXAMINER: Unassigned

ART UNIT: 1615

CONF. NO: 9528

**Supplemental Information Disclosure Statement Within Three Months  
of Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

☒ Copies of the following references are enclosed:

☒ All cited references except U.S. patents and publications.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: April 18, 2005

Judy M. Mohr  
Judy M. Mohr  
Registration No. 38,563

**Correspondence Address:**

Customer No. 22918  
(650) 838-4300



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
Form PTO-1449 (Modified)  
(Use several sheets if necessary)

**COMPLETE IF KNOWN**

Application Number	10/714,085
Confirmation Number	9528
Filing Date	November 14, 2003
First Named Inventor	Zalipsky & Gabizon
Group Art Unit	1615
Examiner Name	Unassigned
Attorney Docket No.	55325-8167.US06

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
		2004/161455	A1	Gabizon, <i>et al.</i>	08/19/04	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent or Application			Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)			
		FR	2 254 336		Kyowa Hakko Kogyo KK	07/11/75	
		PCT	WO 9736904		Sagami Chem Res	10/09/97	
		PCT	WO 99/29302		Sjoeberg, <i>et al.</i>	06/17/99	
		PCT	WO 00/64484		Hadasit Med Res, <i>et al.</i>	11/02/00	

**OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
		Diaz, <i>et al.</i> , <i>Bioconjugate Chem</i> 9:250-254, (1998).	
		Vaage, J., <i>et al.</i> , <i>Intl J Cancer</i> 51(6):942-948, (1992).	
		Zalipsky, S., <i>et al.</i> , 28 <sup>th</sup> International Symposium on Controlled Release of Bioactive Materials and 4 <sup>th</sup> Consumer & Diversified Products Conference, San Diego, CA, Publisher: Controlled Release Society 1:437-438, (2001).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	